ADDERALL XRª should be given upon awakening. Afternoon doses should be avoided because of the potential for insomnia. Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy. HOW SUPPLIED ADDERALL XRª 5 mg Capsules: Clear/ blue (imprinted ADDERALL XR 5 mg), bottles of 100, NDC 54092-381-01 ADDERALL XRª 10 mg Capsules: Blue/ blue (imprinted SHIRE 381 10 mg), bottles of 100, NDC 54092-383-01 ADDERALL XRª 15 mg Capsules: Blue/ white (imprinted ADDERALL XR 15 mg), bottles of 100, NDC 54092-385-01 ADDERALL XRª 20 mg Capsules: Orange/ orange (imprinted SHIRE 381 20 mg), bottles of 100, NDC 54092-387-01 ADDERALL XRª 25 mg Capsules: Orange/ white (imprinted ADDERALL XR 25 mg), bottles of 100, NDC 54092-389-01 ADDERALL XRª 30 mg Capsules: Natural/ orange (imprinted SHIRE 381 30 mg), bottles of 100, NDC 54092-391-01 Dispense in a tight, light-resistant container as defined in the USP. Store at 25º C (77º F). Excursions permitted to 15-30º C (59-86º F) [see USP Controlled Room Temperature] ANIMAL TOXICOLOGY Acute administration of high doses of amphetamine (d-or d, l-) has been shown to produce long-lasting neurotoxic effects, including irreversible nerve fiber damage, in rodents. The significance of these findings to humans is unknown. Manufactured by DSM Pharmaceuticals Inc., Greenville, North Carolina 27834. Distributed and marketed by Shire US Inc., Florence, KY 41042 For more information call 1-800-536-7878 or visit www. adderallxr. com ADDERALL ® is registered in the US Patent and Trademark Office 403957 (rev. 06/ 2002) | ||||
Email this article
Printer friendly
Bookmark this pageadvertisement
